ClinicalTrials.gg
CompletedNCT02013609Updated Mar 29, 2016Results posted

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

A Phase 3 interventional study of Brexpiprazole in MDD, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 24 sites in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2016-03-29.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
19th of 28
48 · median 155
Started
2013
with 5 others
Phase 3
16 of 28
none open now
Registered
16th of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 19th largest by enrollment, is one of 6 that started in 2013, is one of 16 in phase 3, and was the 16th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response in a school or work environment.

03

Conditions studied

  • MDD

Keywords

  • schizophrenia
  • Major depressive disorder
  • Anxiety Symptoms
  • School, Work environment
  • Mental Disorders
  • Psychotic Disorders
  • antipsychotic
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

Have a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by the , Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by both the Mini International Neuropsychiatric Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation.

Have a treatment history of an inadequate ADT response to at least 1 ADT (but not > 3) for the current episode.

Have received a single, trial-approved, SSRI or SNRI at an adequate dose for ≥ 6 weeks prior to screening.

Are 18 to 35 years old at the time of consent (inclusive, and outpatients only).

Are (and will be) working 20 hours or more per week or a student taking 6 credit hours or more during the trial period, however minor deviations from the "part-time" concept may be acceptable on a case-by-case basis based on approval of the medical monitor.

Have a Hamilton Depression Rating Scale (HAM-D)- 17-item Total Score ≥ 18 at screening and baseline.

Have a Sheehan Disability Scale (SDS) 3-item mean score ≥ 5 at baseline.

Main Exclusion Criteria:

Subjects with any of the following current Axis I DSM-IV-TR diagnoses: delirium, dementia, amnestic, or other cognitive disorders; schizophrenia, schizoaffective disorder, or other psychotic disorders; bipolar I disorder, bipolar II disorder, or bipolar disorder not otherwise specified (NOS); eating disorders (including anorexia nervosa or bulimia); obsessive compulsive disorder; panic disorder; post-traumatic stress disorder; and attention deficit hyperactivity disorder.

Subjects with any of the following current Axis II DSM-IV-TR diagnoses: borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorders, or mental retardation.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Up to 3mg/day, once daily dose, tablets, orally

    Drug: Brexpiprazole

Interventions

  • Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). Detailed instructions for administration of this structured interview was provided in the SIGMA. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Mean Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S) Total Score

    The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline and Week 12

  2. Mean Clinical Global Impression-Improvement (CGI-I) Score at Week 12

    The improvement of each participants condition was rated for each participant using the CGI-I. The study physician rated the participants total improvement whether or not it was due entirely to drug treatment. To perform this assessment, the study physician answered the following question: "Compared to his/her condition at baseline, how much has the participant changed?" Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared with the participants condition at Baseline prior to the first dose of study medication.

    Time frame: Weeks 1, 2, 3, 4, 5, 6, 8, 10 and 12

  3. Number of Participants With CGI-I Response

    The CGI-I response rate was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).

    Time frame: Weeks 1, 2, 3, 4, 6, 8 ,10 and 12

  4. Percentage of Participants With MADRS Response

    MADRS response rate was defined as ≥ 50% reduction in respective total scores from Baseline to Week 12.

    Time frame: Baseline and Week 12

  5. Percentage of Participants With MADRS Remission

    MADRS remission rate, where remission is defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score from Baseline to Week 12.

    Time frame: Baseline and Week 12

  6. Mean Change From Baseline to Week 12 in Hamilton Depression Rating Scale (HAM-D17) Total Score

    The HAM-D17 was utilized as an assessment of a participants level of depression and was administered utilizing the Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D). Detailed instructions for administration of this structured interview were provided in the SIGH-D. HAM-D17 is a 17-item questionnaire with a total score of 0 to 52 with higher scores indicating more depressive symptoms.

    Time frame: Baseline and Week 12

  7. Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) 3-item Total/Summed Score

    The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0 = not at all to 10 = extremely. Scores of 5 and above were associated with significant functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).

    Time frame: Baseline and Week 12

  8. Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) Single Item Sub-scores

    The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0 = not at all to 10 = extremely. Scores of 5 and above were associated with significant functional impairment.

    Time frame: Baseline and Week 12

  9. Mean Change From Baseline to Week 12 in Social Adaptation Self-evaluation Scale (SASS) Total Score

    The SASS was a self-rated instrument to assess the social motivation and behavior in participants with depression. It contained 21 items covering the different aspects of social interactions, global social attitude, and self-perception. The SASS total score will be un-evaluable if less than 16 of the 20 items (for item number 1 and item number 2, participant is to answer either one of these) are recorded. If 16 to 19 of the 20 items are recorded, the SASS total score will be the mean of the recorded items multiplied by 20 and then rounded to the first decimal place.Each item is scored from 0 to 3, corresponding to minimal and maximal social adjustment, with a total score range of 0 to 60 (higher scores, indicating worse outcome).

    Time frame: Baseline and Week 12

  10. Mean Change From Baseline to Week 12 in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score

    The MGH-CPFQ was a participant-rated scale designed to assess cognitive and executive dysfunction including symptoms of fatigue in mood and anxiety disorders. The MGH-CPFQ consisted of 7 items, each rated on a scale from 1 (greater than normal functioning) to 6 (poorer than normal functioning). The total score of the 7 items ranged from 7 to 42.

    Time frame: Baseline and Week 12

  11. Mean Change From Baseline to Week 12 in Kellner Symptom Questionnaire (KSQ) Total Score

    KSQ is a subject-rated scale designed to assess distress using symptoms of depression, anxiety, anger-hostility and somatization. The questionnaire contains 92 items of which 68 items indicate symptoms and 24 items are antonyms of some of the symptoms that indicate well-being. The maximum score for each symptom subscale is 17, the well-being subscales 6 and for the total scale scores 23.The total subscale scores will be unevaluable if less than 19 of the 23 items are recorded. If 19 to 22 of the 23 items are recorded, the total subscale score is the mean of the recorded items multiplied by 23 and then rounded to the first decimal place. The total score will be unevaluable if less than 76 of the 92 items are recorded. If 76 to 91 of the 92 items and no less than 19 of the 23 items of each subscale are recorded, the total score will be the mean of the recorded items multiplied by 92 and then rounded to the first decimal place. A higher score indicates more distress than a lower score.

    Time frame: Baseline and Week 12

  12. Mean Change From Baseline to Week 12 in Go/No-Go Task (P-inhibition Failure)

    Executive function and working memory were assessed for the Go/No-go Task using computer-based and paper-pencil neuropsychological instruments. These instruments focused on measuring impulse inhibition. Proportions of inhibitory failures (p-inhibitory failures) is measured as the proportion of no-go targets in the go-cue condition in which a participant failed to inhibit a response.

    Time frame: Baseline and Week 12

  13. Mean Change From Baseline to Week 12 in Go/No-Go Task (Mean Reaction Time)

    Executive function and working memory were assessed for the Go/No-go Task using computer-based and paper-pencil neuropsychological instruments. These instruments focused on measuring impulse inhibition.

    Time frame: Baseline and Week 12

  14. Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) k Value

    Delay discounting was a participant-completed task is an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ. Discounting rate is estimated using, k= (A/V)1/D, where k is the discounting rate parameter, V is the immediate reward, A is the higher delayed reward and D is the amount of days to the delayed reward. The MCQ consists of 27 choices between immediate and delayed rewards. The participant chooses repeatedly between 2 hypothetical sums of money: a smaller amount now or a larger amount in the future (for example, "would you prefer $27 today or $50 in 21 days?") The answers provide an estimate of the participant's discounting rate; higher discounting rates indicate greater impulsivity. A total score is not computed for all 27 questions.

    Time frame: Baseline and Week 12

  15. Mean Change From Baseline to Week 12 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)

    Delay discounting was a participant-completed task considered as an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. During a training session, a single button with letter A or B appeared on the screen. The participant had to wait until the letter began to flash, and press the button only once. An amount of money was added to a counter and another single button appeared. During the test session, both buttons with letters A and B appeared on the screen. The participant had to choose one of the letters that remained; the other disappeared. The participant had to wait until the letter began to flash and then press the button again. An amount of money was added to the counter, and both letters appeared again. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). A total score was not calculated for this task.

    Time frame: Baseline and Week 12

  16. Mean Change From Baseline to Week 12 in Delay and Probability Discounting Task (DPDT)

    The experiential discounting task (EDT) was a subject-completed computerized task designed to measure delay discounting, an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The participant chose between different amounts of money available at different delays or with different chances (probability to get the money). At the end of the session, one of the choices was selected at random, and the participant received whatever they chose in response of that question (immediate, delayed, or probabilistic amount). Formula for h-value:value = A / (1 + hO) p is probability of reward and O is odds against.The value of h indicates how the value of a reward and the probability of its occurrence decreases.The data are computerized and reflect delay discounting and impulsivity (higher discounting and higher probability discounting shows greater impulsivity). A total score is not computed for this task.

    Time frame: Baseline and Week 12

  17. Mean Change From Baseline in Food Delay Discounting Task (DDT)

    Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chooses between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for food is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Food value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

    Time frame: Baseline and Week 12

  18. Mean Change From Baseline in Money Delay Discounting Task

    Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chose between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for money is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Money value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

    Time frame: Baseline and Week 12

  19. Mean Change From Baseline to Week 12 in Barratt Impulsiveness Scale 11-Item (BIS-11) Total Score

    The BIS-11 was a participant-rated scale designed to assess impulsive personality traits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). The scores provided information to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and 3 second-order factors (motor impulsiveness, non-planning impulsiveness, and attentional impulsiveness). The total score ranged from 30 to 120, with higher scores indicating impulsive personality traits.

    Time frame: Baseline and Week 12

07

Results

Posted Mar 29, 2016

Participant flow

This trial was conducted in 48 participants at 24 sites in the United States; 15 of the 24 trial sites enrolled participants.

Participant flow — Overall Study
MilestoneBrexpiprazole
Started47
Completed29
Not completed18
Withdrew: Withdrawal by subject9
Withdrew: Lost to follow-up3
Withdrew: Adverse event3
Withdrew: Met withdrawal criteria3

Outcome measures

PrimaryMean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score

The MADRS was utilized as the primary efficacy assessment of the participant's level of depression and was administered utilizing the Structured Interview Guide for the MADRS (SIGMA). Detailed instructions for administration of this structured interview was provided in the SIGMA. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score-18.1 ± 1.4
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001Mixed model repeated measure (MMRM) with model terms: Baseline, visit, and Baseline by visit interaction
SecondaryMean Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S) Total Score

The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S) Total Score-2.0 ± 0.2
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM with model terms: Baseline, visit, and Baseline by visit interaction
SecondaryMean Clinical Global Impression-Improvement (CGI-I) Score at Week 12

The improvement of each participants condition was rated for each participant using the CGI-I. The study physician rated the participants total improvement whether or not it was due entirely to drug treatment. To perform this assessment, the study physician answered the following question: "Compared to his/her condition at baseline, how much has the participant changed?" Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared with the participants condition at Baseline prior to the first dose of study medication.

Time frame:
Weeks 1, 2, 3, 4, 5, 6, 8, 10 and 12
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression-Improvement (CGI-I) Score at Week 12
Units on a scaleBrexpiprazole
Week 1 (N= 46)3.5 ± 0.8
Week 2 (N= 47)3.0 ± 0.8
Week 3 (N= 47)2.8 ± 1.0
Week 4 (N= 47)2.7 ± 1.0
Week 6 (N= 47)2.6 ± 1.3
Week 8 (N= 47)2.5 ± 1.2
Week 10 (N= 47)2.3 ± 1.2
Week 12 (N= 47)2.2 ± 1.3
SecondaryNumber of Participants With CGI-I Response

The CGI-I response rate was defined as a CGI-I score of 1 (very much improved) or 2 (much improved).

Time frame:
Weeks 1, 2, 3, 4, 6, 8 ,10 and 12
Reported as:
Number · participants
Number of Participants With CGI-I Response
participantsBrexpiprazole
Week 1 (N= 46)4
Week 2 (N= 47)12
Week 3 (N= 47)17
Week 4 (N= 47)24
Week 6 (N= 47)27
Week 8 (N= 47)29
Week 10 (N= 47)28
Week 12 (N= 47)30
SecondaryPercentage of Participants With MADRS Response

MADRS response rate was defined as ≥ 50% reduction in respective total scores from Baseline to Week 12.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of particpants
Percentage of Participants With MADRS Response
percentage of particpantsBrexpiprazole
Percentage of Participants With MADRS Response53.2
SecondaryPercentage of Participants With MADRS Remission

MADRS remission rate, where remission is defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score from Baseline to Week 12.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With MADRS Remission
percentage of participantsBrexpiprazole
Percentage of Participants With MADRS Remission42.6
SecondaryMean Change From Baseline to Week 12 in Hamilton Depression Rating Scale (HAM-D17) Total Score

The HAM-D17 was utilized as an assessment of a participants level of depression and was administered utilizing the Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D). Detailed instructions for administration of this structured interview were provided in the SIGH-D. HAM-D17 is a 17-item questionnaire with a total score of 0 to 52 with higher scores indicating more depressive symptoms.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 12 in Hamilton Depression Rating Scale (HAM-D17) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 12 in Hamilton Depression Rating Scale (HAM-D17) Total Score-14.9 ± 1.1
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM with model terms: Baseline, visit, and Baseline by visit interaction.
SecondaryMean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) 3-item Total/Summed Score

The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0 = not at all to 10 = extremely. Scores of 5 and above were associated with significant functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) 3-item Total/Summed Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) 3-item Total/Summed Score-3.74 ± 0.54
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM with model terms: Baseline, visit, and Baseline by visit interaction
SecondaryMean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) Single Item Sub-scores

The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains. The number most representative of how much each area was disrupted by symptoms was marked along the line from 0 = not at all to 10 = extremely. Scores of 5 and above were associated with significant functional impairment.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 12 in Sheehan Disability Scale (SDS) Single Item Sub-scores
Units on a scaleBrexpiprazole
Work/ school-3.5 ± 0.5
Social life-3.9 ± 0.6
Family life/ home responsibilities-3.7 ± 5.0
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001 (The p-value is the same for each of single item sub-scores of tasks: work/ school, social life and family life/ home responsibilities)MMRM with model terms: Baseline, visit, and Baseline by visit interaction
SecondaryMean Change From Baseline to Week 12 in Social Adaptation Self-evaluation Scale (SASS) Total Score

The SASS was a self-rated instrument to assess the social motivation and behavior in participants with depression. It contained 21 items covering the different aspects of social interactions, global social attitude, and self-perception. The SASS total score will be un-evaluable if less than 16 of the 20 items (for item number 1 and item number 2, participant is to answer either one of these) are recorded. If 16 to 19 of the 20 items are recorded, the SASS total score will be the mean of the recorded items multiplied by 20 and then rounded to the first decimal place.Each item is scored from 0 to 3, corresponding to minimal and maximal social adjustment, with a total score range of 0 to 60 (higher scores, indicating worse outcome).

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 12 in Social Adaptation Self-evaluation Scale (SASS) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 12 in Social Adaptation Self-evaluation Scale (SASS) Total Score9.7 ± 1.6
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM with model terms: Baseline, visit, and Baseline by visit interaction
SecondaryMean Change From Baseline to Week 12 in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score

The MGH-CPFQ was a participant-rated scale designed to assess cognitive and executive dysfunction including symptoms of fatigue in mood and anxiety disorders. The MGH-CPFQ consisted of 7 items, each rated on a scale from 1 (greater than normal functioning) to 6 (poorer than normal functioning). The total score of the 7 items ranged from 7 to 42.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 12 in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 12 in Massachusetts General Hospital-Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) Total Score-8.1 ± 1.3
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM with model terms: Baseline, visit, and Baseline by visit interaction
SecondaryMean Change From Baseline to Week 12 in Kellner Symptom Questionnaire (KSQ) Total Score

KSQ is a subject-rated scale designed to assess distress using symptoms of depression, anxiety, anger-hostility and somatization. The questionnaire contains 92 items of which 68 items indicate symptoms and 24 items are antonyms of some of the symptoms that indicate well-being. The maximum score for each symptom subscale is 17, the well-being subscales 6 and for the total scale scores 23.The total subscale scores will be unevaluable if less than 19 of the 23 items are recorded. If 19 to 22 of the 23 items are recorded, the total subscale score is the mean of the recorded items multiplied by 23 and then rounded to the first decimal place. The total score will be unevaluable if less than 76 of the 92 items are recorded. If 76 to 91 of the 92 items and no less than 19 of the 23 items of each subscale are recorded, the total score will be the mean of the recorded items multiplied by 92 and then rounded to the first decimal place. A higher score indicates more distress than a lower score.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 12 in Kellner Symptom Questionnaire (KSQ) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 12 in Kellner Symptom Questionnaire (KSQ) Total Score-30.5 ± 3.6
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM with model terms: Baseline, visit, and Baseline by visit interaction
SecondaryMean Change From Baseline to Week 12 in Go/No-Go Task (P-inhibition Failure)

Executive function and working memory were assessed for the Go/No-go Task using computer-based and paper-pencil neuropsychological instruments. These instruments focused on measuring impulse inhibition. Proportions of inhibitory failures (p-inhibitory failures) is measured as the proportion of no-go targets in the go-cue condition in which a participant failed to inhibit a response.

Time frame:
Baseline and Week 12
Reported as:
Mean · failures
Mean Change From Baseline to Week 12 in Go/No-Go Task (P-inhibition Failure)
failuresBrexpiprazole
P-inhibition failures (Go cues)0.052 ± 0.299
P-inhibition failures (No-Go cues)0.052 ± 0.295
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.3439p-value for change from Baseline using t-test.
  • Brexpiprazole · t-test, 2 sided · p = 0.3385p-value for change from Baseline using t-test.
SecondaryMean Change From Baseline to Week 12 in Go/No-Go Task (Mean Reaction Time)

Executive function and working memory were assessed for the Go/No-go Task using computer-based and paper-pencil neuropsychological instruments. These instruments focused on measuring impulse inhibition.

Time frame:
Baseline and Week 12
Reported as:
Mean · milliseconds
Mean Change From Baseline to Week 12 in Go/No-Go Task (Mean Reaction Time)
millisecondsBrexpiprazole
Mean reaction time (Go cues)-17.35 ± 73.34
Mean reaction time (No-Go cues)-12.99 ± 70.67
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.2052p-value for change from Baseline using t-test.
  • Brexpiprazole · t-test, 2 sided · p = 0.3224p-value for change from Baseline using t-test.
SecondaryMean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) k Value

Delay discounting was a participant-completed task is an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ. Discounting rate is estimated using, k= (A/V)1/D, where k is the discounting rate parameter, V is the immediate reward, A is the higher delayed reward and D is the amount of days to the delayed reward. The MCQ consists of 27 choices between immediate and delayed rewards. The participant chooses repeatedly between 2 hypothetical sums of money: a smaller amount now or a larger amount in the future (for example, "would you prefer $27 today or $50 in 21 days?") The answers provide an estimate of the participant's discounting rate; higher discounting rates indicate greater impulsivity. A total score is not computed for all 27 questions.

Time frame:
Baseline and Week 12
Reported as:
Mean · unitless
Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) k Value
unitlessBrexpiprazole
Mean Change From Baseline in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) k Value0.009531 ± 0.055516
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.3169p-value for change from Baseline using t-test.
SecondaryMean Change From Baseline to Week 12 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)

Delay discounting was a participant-completed task considered as an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. During a training session, a single button with letter A or B appeared on the screen. The participant had to wait until the letter began to flash, and press the button only once. An amount of money was added to a counter and another single button appeared. During the test session, both buttons with letters A and B appeared on the screen. The participant had to choose one of the letters that remained; the other disappeared. The participant had to wait until the letter began to flash and then press the button again. An amount of money was added to the counter, and both letters appeared again. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). A total score was not calculated for this task.

Time frame:
Baseline and Week 12
Reported as:
Mean · Number of Impulsive Choices
Mean Change From Baseline to Week 12 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)
Number of Impulsive ChoicesBrexpiprazole
Mean Change From Baseline to Week 12 in the Number of Impulsive Choices in the Delayed Reward Task (DRT)3.6 ± 15.2
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.3352
SecondaryMean Change From Baseline to Week 12 in Delay and Probability Discounting Task (DPDT)

The experiential discounting task (EDT) was a subject-completed computerized task designed to measure delay discounting, an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The participant chose between different amounts of money available at different delays or with different chances (probability to get the money). At the end of the session, one of the choices was selected at random, and the participant received whatever they chose in response of that question (immediate, delayed, or probabilistic amount). Formula for h-value:value = A / (1 + hO) p is probability of reward and O is odds against.The value of h indicates how the value of a reward and the probability of its occurrence decreases.The data are computerized and reflect delay discounting and impulsivity (higher discounting and higher probability discounting shows greater impulsivity). A total score is not computed for this task.

Time frame:
Baseline and Week 12
Reported as:
Mean · unitless
Mean Change From Baseline to Week 12 in Delay and Probability Discounting Task (DPDT)
unitlessBrexpiprazole
Delay Discounting Task k value21.315241 ± 116.798133
Delay Discounting Task h value10.350419 ± 60.212518
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.3517
  • Brexpiprazole · t-test, 2 sided · p = 0.3799
SecondaryMean Change From Baseline in Food Delay Discounting Task (DDT)

Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chooses between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for food is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Food value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

Time frame:
Baseline and Week 12
Reported as:
Mean · unitless
Mean Change From Baseline in Food Delay Discounting Task (DDT)
unitlessBrexpiprazole
Mean Change From Baseline in Food Delay Discounting Task (DDT)0.3487 ± 1.4158
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.2610
  • Brexpiprazole · t-test, 2 sided · p = 0.8138
SecondaryMean Change From Baseline in Money Delay Discounting Task

Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chose between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for money is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Money value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

Time frame:
Baseline and Week 12
Reported as:
Mean · unitless
Mean Change From Baseline in Money Delay Discounting Task
unitlessBrexpiprazole
Mean Change From Baseline in Money Delay Discounting Task-0.0095 ± 0.1859
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.8138
SecondaryMean Change From Baseline to Week 12 in Barratt Impulsiveness Scale 11-Item (BIS-11) Total Score

The BIS-11 was a participant-rated scale designed to assess impulsive personality traits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). The scores provided information to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and 3 second-order factors (motor impulsiveness, non-planning impulsiveness, and attentional impulsiveness). The total score ranged from 30 to 120, with higher scores indicating impulsive personality traits.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 12 in Barratt Impulsiveness Scale 11-Item (BIS-11) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 12 in Barratt Impulsiveness Scale 11-Item (BIS-11) Total Score-7.1 ± 1.5
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM with model terms: Baseline, visit, and Baseline by visit interaction

Adverse events

Collected over Adverse events were reported from the signing of the informed consent until the last dose of brexpiprazole with a safety follow-up of 30 (+2) days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole—0/47 (0%)39/47 (83%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBrexpiprazole
HeadacheNervous system disorders10/47
Weight increasedInvestigations8/47
SomnolenceNervous system disorders8/47
AnxietyPsychiatric disorders6/47
NauseaGastrointestinal disorders5/47
InsomniaPsychiatric disorders5/47
DiarrhoeaGastrointestinal disorders4/47
DizzinessNervous system disorders4/47
SedationNervous system disorders4/47
Abdominal DiscomfortGastrointestinal disorders3/47

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Brexpiprazole
Mean26.6 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole
Female32
Male15
08

Study locations

24 sites
  • Cerritos, California 90703, United States
  • Costa Mesa, California 92626, United States
  • Garden Grove, California 92845, United States
  • Glendale, California 91206, United States
  • Orange, California 92868, United States
  • Riverside, California 92506, United States
  • San Diego, California 92121, United States
  • Norwich, Connecticut 06360, United States
  • Fort Myers, Florida 33912, United States
  • Hialeah, Florida 33016, United States
  • Melbourne, Florida 32901, United States
  • Orlando, Florida 32806, United States
  • Atlanta, Georgia 30328, United States
  • Prairie Village, Kansas 66206, United States
  • Weymouth, Massachusetts 02190, United States
  • Las Vegas, Nevada 89102, United States
  • Brooklyn, New York 11235, United States
  • Jamaica, New York 11235, United States
  • Staten Island, New York 10312, United States
  • Portland, Oregon 97210, United States
  • Austin, Texas 78731, United States
  • Houston, Texas 77007, United States
  • San Antonio, Texas 78229, United States
  • Seattle, Washington 98104, United States
09

References and documents

Publications

  • Weiss C, Meehan SR, Brown TM, Gupta C, Morup MF, Thase ME, McIntyre RS, Ismail Z. Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews. J Patient Rep Outcomes. 2021 Dec 11;5(1):128. doi: 10.1186/s41687-021-00380-4. PubMed 34894307 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Sep 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2013
First posted
Dec 17, 2013
Start
Nov 2013
Primary completionActual
Sep 2014
CompletionActual
Oct 2014
Results first posted
Mar 29, 2016
Last update
Mar 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02013609
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
Nov 2013
Primary completion
Sep 2014
Completion
Oct 2014
Results posted
Mar 29, 2016
Last update
Mar 29, 2016

Study contacts

Junichi Hashimoto, PhD
study director · Otsuka Pharmaceutical Co., Ltd Japan (OPCJ)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion